TARGET
saveKRAS G12C
KRAS with G12C mutation; approved druggable RAS allele.
also known as: g12c, sotorasib target, adagrasib target
drugs
0
catalysts
0
news
20
companies
0
Top drugs
no drugs tagged with this interest yet
🐶 Top companies
no companies tagged with this interest yet
Recent catalysts
no catalysts tagged with this interest yet
Recent news
view all →- RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancerbiospace · 1mo ago
- Hansoh heralds China’s move from ‘follower’ to ‘frontrunner’ in biopharma racefiercebiotech · 1mo ago
- After some ‘tough years,’ Frontier’s CEO is ramping up ambitions for precision med platformfiercebiotech · 1mo ago
- Roche KRAS drug succeeds in head-to-head lung cancer studybiopharma dive · 3mo ago
- Roche’s KRAS G12C inhibitor beats rivals in head-to-head Phase 3 studyendpoints · 3mo ago
- Dr Pant on the Mechanism of Action of Daraxonrasib in PDAConclive · 5mo ago
Data sources
last refreshed 28m ago
Found something off?
comments(0)
5-min edit window · permanent after that